Skip to main content

“AIDS is Not a Business”: A Study in Global Corporate Responsibility – Securing Access to Low-cost HIV Medications

Abstract

At the end of the 1990s, Brazil was faced with a potentially explosive HIV/AIDS epidemic. Through an innovative and multifaceted campaign, and despite initial resistance from multinational pharmaceutical companies, the government of Brazil was able to negotiate price reductions for HIV medications and develop local production capacity, thereby averting a public health disaster. Using interview data and document analysis, the authors show that the exercise of corporate social responsibility can be viewed in practice as a dynamic negotiation and an interaction between multiple actors. Action undertaken in terms of voluntary CSR alone may be insufficient. This finding highlights the importance of a strong role for national governments and international organizations to pressure companies to perform better.

This is a preview of subscription content, access via your institution.

References

  • Abbott F. M. (2002). The Doha Declaration on the TRIPS Agreement and Public Health: Lighting a Dark Corner at the WTO. Journal of International Economic Law 5(2):469–505

    Article  Google Scholar 

  • Attaran, A.: 2002, ‘The Doha Declaration of the TRIPS Agreement and Public Health, Access to Pharmaceuticals, and Options under WTO Law’, Fordham Intellectual Property, Media and Entertainment Law Journal 12, 859–885.

  • BMS: 2006, ‘The Bristol-Myers Squibb Pledge’, http://www.bms.com/aboutbms/content/data/ourple.html, 04/23/2006.

  • Carroll A. (1999). Corporate Social Responsibility. Business and Society 38(3):268–295

    Article  Google Scholar 

  • Carroll A. (1991). The Pyramid of Corporate Social Responsibility: Toward the Moral Management of Organizational Stakeholders. Business Horizons 34:39–48

    Article  Google Scholar 

  • Champ P., Attaran A. (2002). Patent Rights and Local Working under the WTO TRIPS Agreement: An Analysis of the U.S.–Brazil Patent Dispute. Yale Journal of International Law 27:365–393

    Google Scholar 

  • Christmann P., Taylor G. (2001). Globalization and the Environment: Determinants of Firm Self-Regulation in China. Journal of International Business Studies 32:439–458

    Article  Google Scholar 

  • Commission on Intellectual Property Rights: 2002, Integrating Intellectual Property Rights and Development Policy (London), http://www.iprcommission.org

  • Correa C. M., Yusuf A. A. (eds) (1998). Intellectual Property and International Trade: The TRIPS Agreement. Kluwer Law, London

    Google Scholar 

  • Dowell G., Hart S., Yeung B. (2000). Do Corporate Environmental Standards Create or Destroy Market Value?. Management Science 46:1059–1074

    Article  Google Scholar 

  • Ford S. M. (2000). Compulsory Licensing Provisions Under TRIPS Agreement: Balancing Pills and Patents. American University International Law Review 15:941

    Google Scholar 

  • Hammersley M., Atkinson P. (1995). Ethnography: Principles in Practice, 2nd edn. Routledge, London

    Google Scholar 

  • Jordan, M.: 2003, ‘Brazil to Stir Up AIDS-Drug Battle’ Wall Street Journal, Sept. 5

  • Kolk A. (2005). Environmental Reporting by Multinationals from the Triad: Convergence or Divergence?. Management International Review 45(Special Issue 1):145–167

    Google Scholar 

  • Kolk A., van Tulder R. (2002). International Codes of Conduct: Trends, Sectors, Issues and Effectiveness. Erasmus University, Rotterdam

    Google Scholar 

  • Kolk A., van Tulder R. (2004). Ethics in International Business: Multinational Approaches to Child Labor. Journal of World Business 39:49–60

    Article  Google Scholar 

  • Lacayo A. (2002). Seeking a Balance: International Pharmaceutical Patent Protection, Public Health Crisis, and the Emerging Threat of Bio-Terrorism. University of Miami Inter-American Law Review 33(Part 2/3):295–324

    Google Scholar 

  • Merck: 2006a, ‘Mission Statement’, http://www.merck.com/about/mission.html, 04/23/2006

  • Merck: 2006b, ‘Corporate Responsibility’, http://www.merck.com/about/cr/, 04/23/2006

  • OECD: 2001, ‘Making Codes of Corporate Conduct Work: Management Control Systems and Corporate Responsibility’, Working Papers on International Investment, Number 2001/3 (OECD, Paris), http://www.oecd.org/pdf/M00015000/M00015442.pdf

  • Osava, M.: 2004, ‘Lula Pressing for New Drug-Price Cuts in AIDS Fight’, IPS-Inter Press Service, January 14.

  • Roche: 2006a, ‘CEO Message’, http://www.roche.com/home/company/com_ceo_read.htm, 04/23/2006

  • Roche: 2006b, ‘Our Social Commitments: Introduction and Key Note’, http://www.rocheindia.com/Company_OurSocialCommitments.htm, 05/12/2006.

  • Scherer F. M., Watal J. (2002). Post-TRIPS Options for Access to Patented Medications in Developing Nations. Journal of International Economic Law 5(4):913–939

    Article  Google Scholar 

  • Schlegelmilch B. B., Robertson D. C. (1995). The Influence of County and Industry on Ethical Perspectives of Senior Executives in the US and Europe. Journal of International Business Studies 26:859–881

    Article  Google Scholar 

  • Sell S. K. (2002). TRIPS and Access to Medicines Campaign. Wisconsin International Law Journal 20(481):500–521

    Google Scholar 

  • Sykes A. O. (2002). TRIPS, Pharmaceuticals, Developing Countries and the Doha “Solution”. Chicago Journal of International Law 3:47–68

    Google Scholar 

  • t’Hoen E. (2002). TRIPS, Pharmaceutical Patents and Access to Essential Medicines: A Long Way from Seattle to Doha. Chicago Journal of International Law 3(1):27–43

    Google Scholar 

  • Thomas J. S., Meyer M. A. (1997). The New Rules of Global Trade. Carswell, Toronto

    Google Scholar 

  • TRIPS: 1994, ‘Agreement on Trade-related Aspects of Intellectual Property Rights’, Appendix 1C of the Agreement Establishing the World Trade Organization (Marrakesh, Morocco, April 15), http://www.wto.org/english/docs_e/legal_e/27-trips_01_e.htm

  • UNAIDS: 2006, Fact Sheet 06 (Joint United Nations Programme on HIV/AIDS), http://www.data.unaids.org/pub/GlobalReport/2006/200605-FS_LatinAmerica_en.pdf

  • UNGASS: 2001, United Nations General Assembly Special Session on HIV/AIDS (June 27), http://www.un.org/ga/aids/docs/aress262.pdf.

  • UNHCHR: 2001, ‘Economic, Social and Cultural Rights: The Impact of the Agreement on Trade-related Aspects of Intellectual Property Rights on Human Rights’, Report of the United Nations [UN] High Commissioner for Human Rights, E/CN.4/Sub.2/2001/13; 27 (June 2001).

  • van Tulder R., Kolk A. (2001). Multinationality and Corporate Ethics: Codes of Conduct in the Sporting Goods Industry. Journal of International Business Studies 32:267–283

    Article  Google Scholar 

  • Viana J. M. N. (2002). Intellectual Property Rights, the World Trade Organization and Public Health: The Brazilian Perspective. Connecticut Journal of International Law 311(17):311–317

    Google Scholar 

  • WHO: 2002, Press Release (WHO/58, July 9), http://www.who.int/inf/en/pr-2002-58.html

  • Watal J. (2001). Intellectual Property Rights in the WTO and Developing Countries. Kluwer Law, The Hague

    Google Scholar 

  • Wood D. (1991). Corporate Social Performance Revisited. Academy of Management Review 16(4):691–718

    Article  Google Scholar 

  • World Bank (2004). Battling HIV/AIDS: A Decision Maker’s Guide to the Procurement of Medicines and Related Supplies. World Bank, Washington, DC

    Google Scholar 

  • World Bank: 2006, ‘Brazil Data Profile’, http://www.devdata.worldbank.org/external/CPProfile.asp?SelectedCountry=BRA&CCODE=BRA&CNAME =Brazil&PTYPE=CP

  • WTO: 2001, Doha Declaration on TRIPS Agreement and Public Health, Adopted November 14, World Trade Organization, Geneva, http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William Flanagan.

Additional information

William Flanagan is the Dean of Law at Queen’s University, Kingston, Ontario. His research interests include international trade and investment, and corporate law and corporate governance.

Gail Whiteman is Assistant Professor in the Department of Business and Society of the Rotterdam School of Management, Erasmus University, The Netherlands.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Flanagan, W., Whiteman, G. “AIDS is Not a Business”: A Study in Global Corporate Responsibility – Securing Access to Low-cost HIV Medications. J Bus Ethics 73, 65–75 (2007). https://doi.org/10.1007/s10551-006-9198-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10551-006-9198-y

Keywords

  • Brazil
  • compulsory licensing
  • corporate social responsibility
  • developing countries
  • HIV/AIDS
  • multinational pharmaceutical companies
  • patents
  • TRIPS
  • WTO